Alamar Biosciences saw its stock price jump 33% on its first day of trading on the Nasdaq on Friday, valuing the protein biomarker detection platform company at $1.53 billion. The Fremont, California-based company opened at $22.60 per share, after pricing its initial public offering at $17 per share. Alamar increased the size of its offering, pricing at the top of its $15 to $17 range. It sold approximately 11.3 million shares, raising $191.3 million. Founded in 2018, the company focuses on developing devices that can detect low-concentration protein biomarkers in blood for disease research and diagnostics.